Husch Blackwell was recognized by Patexia, the world’s largest network for intellectual property professionals, in its inaugural ANDA Litigation Intelligence Report as being among the top 50 law firms handling Abbreviated New Drug Application (ANDA) litigation. The study measured the performance and activity of stakeholder organizations, including attorneys, law firms, pharmaceutical companies and judges.
Patexia evaluated over 240 law firms and 1,105 attorneys over a three-year period ending in June 2020. The study analyzed nearly 1,000 cases involving over 1,300 patents.
Husch Blackwell’s ANDA litigation team placed among the top 30 of most active law firms representing generic drug makers as defendants in ANDA litigation, with eight cases appearing in the study. Partner Don Mizerk highlighted the team’s work, garnering an individual ranking among the most active ANDA attorneys on the defendant side. The firm was also ranked among the top 50 for its performance on behalf of defendants in ANDA litigation.
Husch Blackwell’s ANDA litigation team spans multiple offices and is comprised of 13 lawyers, two scientific advisors and one dedicated paralegal. The team has handled litigation involving blockbuster drug categories, including anticoagulants, antidepressants, H1 antagonists, and antiarrhythmic agents, among others.